Patent · US Active

Highly efficient influenza matrix (M1) proteins

US8992939B2 · kind B2 · utility

11Cited by

9References

20Claims

0Family size

Assignee

Novavax, Inc. · US

Inventors

Gale Smith · Germantown, US
Yingyun Wu · Clarksburg, US
Michael J. MASSARE · Mount Airy, US
Peter Pushko · Frederick, US
Margret Nathan · West Chester, US
Thomas Kort · Rockville, US
Robin Robinson · Dickerson, US

Key dates

Filing date	Oct 24, 2011
Grant date	Mar 31, 2015
Priority date	—
Expiry date	Oct 31, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/22
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.